FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

GALLISPAT Share Price Discussion

Gallantt Ispat Ltd.
Sector: Iron and Steel
... Read more
GALLISPAT Long Term Analysts Rating
0/5 (0 Ratings)
GALLISPAT Share Price *
27.7 +0.35 (1.28%)
* (quote may be delayed)

Find answers to all your questions on live GALLISPAT message board: Is GALLISPAT buy or sell? Should I buy GALLISPAT shares? Why are GALLISPAT shares falling? Should I invest in GALLISPAT stock?


GALLISPAT Discussion Forum

@newsbot • Reputation: 1,965
GlaxoSmithKline Consolidated September 2019 Net Sales at Rs 882.02 crore, up 0% Y-o-Y
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,965
GSK Pharma Q2 profit at Rs 503 cr
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,965
GSK Pharma slips 5% after halting sale of acidity medicine Zinetac, other ranitidine products
The company has made the decision to initiate a voluntary recall of Zinetac Tablets 150 mg and 300 mg products manufactured in India.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,965
Government scrambles to address shortage of rabies vaccine after GSK exit
Sources within the vaccine industry said that one of the main reasons for the current shortage was due to the exit of Chiron Behring Vaccines, a unit of GlaxoSmithKline (GSK).
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,965
Focus on selective products, therapies starting to pay dividends: GSK Pharma
Vaidheesh hinted at new launches such as a vaccine (Bexsero) to protect infants against Meningitis B and a new drug to treat autoimmune disorders
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,965
Hold GlaxoSmithKline Consumer Healthcare; target of Rs 7972: Prabhudas Lilladher
Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 1,965
Like
reply
Reply
@newsbot • Reputation: 1,965
Like
reply
Reply
@newsbot • Reputation: 1,965
Like
reply
Reply
@newsbot • Reputation: 1,965
Like
reply
Reply
@newsbot • Reputation: 1,965
Like
reply
Reply
@newsbot • Reputation: 1,965
Like
reply
Reply
@newsbot • Reputation: 1,965
Like
reply
Reply
@newsbot • Reputation: 1,965
Like
reply
Reply
  • GALLISPAT - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization851.44
    Enterprise Value1,090.09
    Price to Earnings14.12
    Price to Book Value1.11
    Return on Capital Employed0.11
    Return on Equity0.12
    Face Value1
    Dividend YieldNA
  • GALLISPAT Share Price - Technicals

    keyboard_arrow_down
    GALLISPAT - 52 Week High₹44
    GALLISPAT - 52 Week Low₹16.05
  • GALLISPAT Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jan 2426.8527.725.727.25
    Jan 2328.0528.625.6527.35
    Jan 2228.5528.552828.5
    Jan 2128.829.2527.328.9
    Jan 2027.530.42729
  • GALLISPAT Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹27.25
    30 Day Moving Average₹25.21
    50 Day Moving Average₹23.34
    100 Day Moving Average₹22.04
    200 Day Moving Average₹27.44
  • GALLISPAT - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue575424.710.35
    Operating Profit9252.150.76
    Profit Before Tax6746.050.45
    Net Income5444.250.22
  • GALLISPAT - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds7644460.71
    Total Liabilities284563-0.5
    Total Assets1,0481,0100.04
  • GALLISPAT - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity7619.172.96
    Cash from Investing Activity-157-32.913.77
    Cash from Financing Activity8111.915.8
    Net Cash FlowNA-1.83-1
  • GALLISPAT - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.050.06
    Return on Equity0.120.11
    Return on Capital Employed0.110.11
  • GALLISPAT - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.03
    3 Year CAGR Growth in Operating Profit0.78
    3 Year CAGR Growth in EBIDTA0.73
    3 Year CAGR Growth in Net Income0.99
    3 Yr CAGR Growth - Diluted EPS-0.8
  • GALLISPAT - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.4
    5 Year CAGR Growth in Operating Profit2.05
    5 Year CAGR Growth in EBIDTA0.78
    5 Year CAGR Growth in Net Income3.6
    3 Yr CAGR Growth - Diluted EPS3.37
  • GALLISPAT - Recent News

    keyboard_arrow_down
    NewsBot
    Oct 23 5:48 PM
    GlaxoSmithKline Consolidated September 2019 Net Sales at Rs 882.02 crore, up 0% Y-o-Y
    Moneycontrol
    NewsBot
    Oct 22 10:43 PM
    GSK Pharma Q2 profit at Rs 503 cr
    Moneycontrol
    NewsBot
    Sep 26 4:03 PM
    GSK Pharma slips 5% after halting sale of acidity medicine Zinetac, other ranitidine products
    Moneycontrol
    NewsBot
    Sep 4 12:13 AM
    Government scrambles to address shortage of rabies vaccine after GSK exit
    Moneycontrol
    NewsBot
    Aug 21 3:29 PM
    Focus on selective products, therapies starting to pay dividends: GSK Pharma
    Moneycontrol
    NewsBot
    Aug 7 9:38 PM
    Hold GlaxoSmithKline Consumer Healthcare; target of Rs 7972: Prabhudas Lilladher
    moneycontrol.com
    NewsBot
    Jul 22 10:38 PM
    NewsBot
    Jul 22 9:13 PM
    NewsBot
    Jul 22 9:13 PM
    NewsBot
    Jul 16 2:38 AM
  • GALLISPAT - Related Communities

    keyboard_arrow_down
    Tata Steel Ltd. Sector: Iron and Steel
    JSW Steel Ltd. Sector: Iron and Steel
    Jindal Steel & Power Ltd. Sector: Ir...
    Steel Authority of India (SAIL) Ltd. ...
    Jindal Saw Ltd. Sector: Iron and Steel
    Jai Corp Ltd. Sector: Iron and Steel
    Welspun Corp Ltd. Sector: Iron and Steel
    Tata Sponge Iron Ltd. Sector: Iron an...
    Mishra Dhatu Nigam Ltd. Sector: Iron ...
    Tata Metaliks Ltd. Sector: Iron and S...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.